Amundi Has $33.97 Million Stock Holdings in Penumbra, Inc. $PEN

Amundi lessened its holdings in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 23.2% in the first quarter, according to its most recent filing with the SEC. The firm owned 124,309 shares of the company's stock after selling 37,630 shares during the period. Amundi owned 0.32% of Penumbra worth $33,966,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of PEN. Synergy Investment Management LLC acquired a new stake in Penumbra during the 1st quarter worth $27,000. First Horizon Advisors Inc. grew its holdings in Penumbra by 404.8% during the 1st quarter. First Horizon Advisors Inc. now owns 106 shares of the company's stock worth $28,000 after acquiring an additional 85 shares during the period. AlphaQuest LLC acquired a new stake in Penumbra during the 1st quarter worth $66,000. Caitong International Asset Management Co. Ltd acquired a new stake in Penumbra during the 1st quarter worth $76,000. Finally, Versant Capital Management Inc grew its holdings in Penumbra by 893.5% during the 1st quarter. Versant Capital Management Inc now owns 308 shares of the company's stock worth $82,000 after acquiring an additional 277 shares during the period. Institutional investors and hedge funds own 88.88% of the company's stock.

Analyst Upgrades and Downgrades

PEN has been the topic of a number of recent analyst reports. Morgan Stanley lifted their price target on shares of Penumbra from $260.00 to $266.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Citigroup reduced their price target on shares of Penumbra from $320.00 to $285.00 and set a "neutral" rating on the stock in a research report on Wednesday, July 9th. Robert W. Baird lifted their price target on shares of Penumbra from $283.00 to $285.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 30th. Evercore ISI initiated coverage on shares of Penumbra in a research report on Tuesday, September 2nd. They set an "outperform" rating and a $300.00 price target on the stock. Finally, William Blair raised shares of Penumbra to a "strong-buy" rating in a research report on Friday, July 18th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, Penumbra currently has an average rating of "Moderate Buy" and an average target price of $302.93.

Insider Activity

In other news, Director Harpreet Grewal sold 186 shares of the business's stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $272.19, for a total transaction of $50,627.34. Following the transaction, the director directly owned 8,888 shares in the company, valued at $2,419,224.72. The trade was a 2.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Johanna Roberts sold 600 shares of the business's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $270.58, for a total transaction of $162,348.00. Following the transaction, the executive vice president owned 64,857 shares in the company, valued at $17,549,007.06. This represents a 0.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 112,163 shares of company stock worth $27,932,335. 4.20% of the stock is currently owned by company insiders.

Penumbra Stock Down 1.0%

PEN traded down $2.72 during trading on Friday, hitting $273.68. The company had a trading volume of 101,997 shares, compared to its average volume of 493,604. The company has a market capitalization of $10.67 billion, a PE ratio of 72.79, a PEG ratio of 2.45 and a beta of 0.45. Penumbra, Inc. has a one year low of $184.80 and a one year high of $310.00. The firm's 50-day moving average price is $251.62 and its 200 day moving average price is $265.17. The company has a quick ratio of 4.04, a current ratio of 6.75 and a debt-to-equity ratio of 0.02.

Penumbra (NYSE:PEN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.81 by $0.05. The business had revenue of $339.46 million for the quarter, compared to analysts' expectations of $327.37 million. Penumbra had a net margin of 11.54% and a return on equity of 11.55%. The firm's revenue was up 13.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.64 EPS. Penumbra has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.